208 related articles for article (PubMed ID: 7485301)
1. Normal nuchal thickness in the midtrimester indicates reduced risk of Down syndrome in pregnancies with abnormal triple-screen results.
Bahado-Singh RO; Goldstein I; Uerpairojkit B; Copel JA; Mahoney MJ; Baumgarten A
Am J Obstet Gynecol; 1995 Oct; 173(4):1106-10. PubMed ID: 7485301
[TBL] [Abstract][Full Text] [Related]
2. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome.
Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A
Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756
[TBL] [Abstract][Full Text] [Related]
3. The comprehensive midtrimester test: high-sensitivity Down syndrome test.
Bahado-Singh R; Shahabi S; Karaca M; Mahoney MJ; Cole L; Oz UA
Am J Obstet Gynecol; 2002 Apr; 186(4):803-8. PubMed ID: 11967511
[TBL] [Abstract][Full Text] [Related]
4. A high-sensitivity alternative to "routine" genetic amniocentesis: multiple urinary analytes, nuchal thickness, and age.
Bahado-Singh R; Oz U; Kovanci E; Cermik D; Copel J; Mahoney MJ; Cole L
Am J Obstet Gynecol; 1999 Jan; 180(1 Pt 1):169-73. PubMed ID: 9914599
[TBL] [Abstract][Full Text] [Related]
5. Nuchal thickness, urine beta-core fragment level, and maternal age for down syndrome screening.
Bahado-Singh RO; Oz AU; Flores D; Cermik D; Acuna E; Mahoney MJ; Cole L
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 1):491-5. PubMed ID: 9988824
[TBL] [Abstract][Full Text] [Related]
6. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies.
Bahado-Singh RO; Oz U; Shahabi S; Mahoney MJ; Baumgarten A; Cole LA
Am J Obstet Gynecol; 2000 Nov; 183(5):1114-8. PubMed ID: 11084551
[TBL] [Abstract][Full Text] [Related]
7. Critical appraisal of the use of nuchal fold thickness measurements for the prediction of Down syndrome.
Locatelli A; Piccoli MG; Vergani P; Mariani E; Ghidini A; Mariani S; Pezzullo JC
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):192-7. PubMed ID: 10649178
[TBL] [Abstract][Full Text] [Related]
8. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
[TBL] [Abstract][Full Text] [Related]
9. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers.
Nyberg DA; Luthy DA; Cheng EY; Sheley RC; Resta RG; Williams MA
Am J Obstet Gynecol; 1995 Oct; 173(4):1030-5. PubMed ID: 7485289
[TBL] [Abstract][Full Text] [Related]
10. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome.
Lam YH; Lee CP; Sin SY; Tang R; Wong HS; Wong SF; Fong DY; Tang MH; Woo HH
Prenat Diagn; 2002 Aug; 22(8):730-5. PubMed ID: 12210586
[TBL] [Abstract][Full Text] [Related]
11. New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age.
Bahado-Singh RO; Oz AU; Kovanci E; Deren O; Copel J; Baumgarten A; Mahoney J
Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1627-31. PubMed ID: 9855608
[TBL] [Abstract][Full Text] [Related]
12. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
13. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.
Burton BK; Prins GS; Verp MS
Am J Obstet Gynecol; 1993 Sep; 169(3):526-30. PubMed ID: 7690522
[TBL] [Abstract][Full Text] [Related]
14. Prenatal diagnosis of trisomy 21 in monozygotic twins with increased nuchal translucency and abnormal serum biochemistry.
Verdin SM; Braithwaite JM; Spencer K; Economides DL
Fetal Diagn Ther; 1997; 12(3):153-5. PubMed ID: 9313073
[TBL] [Abstract][Full Text] [Related]
15. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.
Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A
Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343
[TBL] [Abstract][Full Text] [Related]
16. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
Wald NJ; Watt HC; Hackshaw AK
N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
[TBL] [Abstract][Full Text] [Related]
17. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
[TBL] [Abstract][Full Text] [Related]
18. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
19. Combined second-trimester biochemical and ultrasound screening for Down syndrome.
Benn PA; Kaminsky LM; Ying J; Borgida AF; Egan JF
Obstet Gynecol; 2002 Dec; 100(6):1168-76. PubMed ID: 12468159
[TBL] [Abstract][Full Text] [Related]
20. Multiple screening for fetal Down's syndrome with the classic triple test, dimeric inhibin A and ultrasound.
Debiève F; Bouckaert A; Hubinont C; Thomas K
Gynecol Obstet Invest; 2000; 49(4):221-6. PubMed ID: 10828702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
